Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
US8329172B2 · kind B2 · utility
58Cited by
52References
1Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 18, 2007 |
| Grant date | Dec 11, 2012 |
| Priority date | — |
| Expiry date | Nov 22, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/77
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.